Treatment and Prognosis of Solid and Cystic Brain Metastases in Patients with Non-Small-Cell Lung Cancer

doi:10.2147/CMAR.S314060

	Treatment and Prognosis of Solid and Cystic Brain Metastases in Patients with Non-Small-Cell Lung Cancer
	Xu, Yi-Bing 1,2; Zhang, Yiping 1,2; Song, Zhengbo 1,2; Wang, Wenxian 1,2; Shao, Lan 1,2
刊名	CANCER MANAGEMENT AND RESEARCH
	2021
卷号	13
关键词	cystic brain metastases tyrosine kinase inhibitors chemotherapy radiation therapy lung cancer
ISSN号	1179-1322
DOI	10.2147/CMAR.S314060
通讯作者	Shao, Lan(shaolan1677@163.com)
英文摘要	Background: Brain metastasis (BM) is an important factor shortening the lives of patients with lung cancer. Patients with cystic BM have seldom been reported. Here, we compared the efficacy and prognosis of different therapeutic schedules for solid BM and cystic BM in patients with non-small cell lung cancer (NSCLC). Methods: A retrospective study was conducted of 355 patients with pathologically confirmed stage IV NSCLC, all of whom had BM. We analyzed the clinical characteristics of these patients and the efficacy of targeted drugs and chemotherapy regimens. Results: A total of 255 patients with solid BM (cohort 1) and 33 patients with cystic BM (cohort 2) had evaluable efficacy. We evaluated these 33 patients in cohort 2. The median progression-free survival (PFS) and overall survival (OS) were 8.4 months and 23.0 months, respectively. A significant difference was observed between targeted regimens and chemotherapy treatment in terms of the PFS (12.6 months vs 6.3 months, P = 0.001) and OS (47.9 months vs 17.0 months, P = 0.007). Multivariate analyses showed that treatment regimen (chemotherapy) was a poor prognostic factor for PFS (P < 0.05). Cystic BM may be more likely to occur in patients with NSCLC with genetic mutations. A difference in prognosis was observed between patients who underwent targeted treatment and chemotherapy. A significant difference in intracranial PFS was observed between cohorts (cohort 1 vs cohort 2: 15.4 months vs 9.9 months, P = 0.015), and this advantage was clear in patients who did not receive targeted therapies (11.7 months vs 6.5 months, P = 0.003). However, the OS in patients with targeted therapies in cohort 2 was significantly longer than that in cohort 1 (23.4 months vs 47.9 months, P = 0.013). Conclusion: Patients with NSCLC, particularly those who develop cystic BM, should be genetically tested as much as possible to find out more suitable drug therapies.
资助项目	Medical Health Science and Technology Project of the Zhejiang Provincial Health Commission[2019RC027]
WOS关键词	RADIOSURGERY ; TUMORS ; TRIAL
WOS研究方向	Oncology
语种	英语
出版者	DOVE MEDICAL PRESS LTD
WOS记录号	WOS:000684201000004
资助机构	Medical Health Science and Technology Project of the Zhejiang Provincial Health Commission
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/124330]
专题	中国科学院合肥物质科学研究院
通讯作者	Shao, Lan
作者单位	1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou 310022, Peoples R China 2.Chinese Acad Sci, Inst Canc & Basic Med IBMC, Hangzhou 310022, Peoples R China
推荐引用方式 GB/T 7714	Xu, Yi-Bing,Zhang, Yiping,Song, Zhengbo,et al. Treatment and Prognosis of Solid and Cystic Brain Metastases in Patients with Non-Small-Cell Lung Cancer[J]. CANCER MANAGEMENT AND RESEARCH,2021,13.
APA	Xu, Yi-Bing,Zhang, Yiping,Song, Zhengbo,Wang, Wenxian,&Shao, Lan.(2021).Treatment and Prognosis of Solid and Cystic Brain Metastases in Patients with Non-Small-Cell Lung Cancer.CANCER MANAGEMENT AND RESEARCH,13.
MLA	Xu, Yi-Bing,et al."Treatment and Prognosis of Solid and Cystic Brain Metastases in Patients with Non-Small-Cell Lung Cancer".CANCER MANAGEMENT AND RESEARCH 13(2021).